ERalpha (Y537S mutant)-pcw107-V5
(Plasmid
#64634)
-
Purposewhen used to produce lentivirus, express physiological levels of insert
-
Depositing Labs
-
Sequence Information
Full plasmid sequence is not available for this item.
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 64634 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepcw107 (V5)
-
Backbone manufacturerJohn Doench/Kathleen Ottina
- Backbone size w/o insert (bp) 9240
-
Vector typeLentiviral
-
Selectable markersPuromycin
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)Stbl3
-
Copy numberUnknown
Gene/Insert
-
Gene/Insert nameESR1 (transcript variant 1)
-
Alt nameNM_000125.3
-
SpeciesH. sapiens (human)
-
Insert Size (bp)1788
-
MutationY537S
-
Entrez GeneESR1 (a.k.a. ER, ESR, ESRA, ESTRR, Era, NR3A1)
- Promoter PGK
-
Tag
/ Fusion Protein
- V5 (C terminal on backbone)
Cloning Information
- Cloning method Gateway Cloning
- 5′ sequencing primer hPGK-F
- 3′ sequencing primer WPRE-R (Common Sequencing Primers)
Resource Information
-
Supplemental Documents
-
A portion of this plasmid was derived from a plasmid made byBenita Katzenellenbogen Lab, UIUC
-
Article Citing this Plasmid
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
Depositor Comments
GCGC (N-term barcode, 17 nt upstream of CDS start). Working name: CTK-O1-V5
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
ERalpha (Y537S mutant)-pcw107-V5 was a gift from David Sabatini & Kris Wood (Addgene plasmid # 64634 ; http://n2t.net/addgene:64634 ; RRID:Addgene_64634) -
For your References section:
Systematic identification of signaling pathways with potential to confer anticancer drug resistance. Martz CA, Ottina KA, Singleton KR, Jasper JS, Wardell SE, Peraza-Penton A, Anderson GR, Winter PS, Wang T, Alley HM, Kwong LN, Cooper ZA, Tetzlaff M, Chen PL, Rathmell JC, Flaherty KT, Wargo JA, McDonnell DP, Sabatini DM, Wood KC. Sci Signal. 2014 Dec 23;7(357):ra121. doi: 10.1126/scisignal.aaa1877. 10.1126/scisignal.aaa1877 PubMed 25538079